Pevonedistat - Takeda Oncology

Drug Profile

Pevonedistat - Takeda Oncology

Alternative Names: MLN-4924; MLN4924-003; Pevonedistat hydrochloride; TAK 924

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Millennium Pharmaceuticals
  • Developer Children's Oncology Group; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); Takeda Oncology; University of Miami; University of Michigan Comprehensive Cancer Center; University of Southern California; University of Texas M. D. Anderson Cancer Center; Vanderbilt-Ingram Cancer Center; Washington University School of Medicine
  • Class 2 ring heterocyclic compounds; Amines; Antineoplastics; Cyclopentanes; Indenes; Pyrimidines; Pyrroles; Small molecules; Sulfonic acids
  • Mechanism of Action NEDD 8 activating enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelodysplastic syndromes; Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Phase II Myeloproliferative disorders; Non-small cell lung cancer
  • Phase I/II Mesothelioma
  • Phase I Lymphoma; Myelofibrosis; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours

Most Recent Events

  • 13 Aug 2018 Phase-I clinical trials in Solid tumours (Combination therapy, Second-line therapy or greater, In adults, In the elderly, Late-stage disease, Metastatic disease) in USA (IV) (NCT03486314)
  • 24 Jun 2018 Biomarkers information updated
  • 14 Jun 2018 Adverse events and efficacy data from a phase I trial in Acute myeloid leukaemia and Myelodysplastic syndromes presented at the 23rd Congress of the European Haematology Association (EHA-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top